On Nov. 17, 1993, Genentech drug Nutropin was approved by the U.S. Food and Drug Administration (FDA) for the treatment of children with growth failure associated with chronic renal insufficiency. 

The drug received additional approvals for other indications and formulations, including Nutropin AQ in 1995 and Nutropin Depot in 1999.